Representatives from AstraZeneca, Pfizer, GlaxoSmithkline, Amgen, and other firms were at Amgen’s new European HQ in Uxbridge to discuss how to maintain the UK’s competitive edge in the biotech and pharmaceutical industries. The discussions covered the cost of clinical trials, strengthening links with universities and funding.
Speaking prior to the meeting, Mr Blair said: “To allow the biotech industry to get some strength in research out of the NHS is something we need to look at in this country.
“The fact that we can get the best people in from around the world to work in the UK is another enormous strength.”
The UK accounts for just under half of public biotech companies in Europe, and has three times more than that of its nearest rival Germany. The prime minister added that he believes that the industry and Government have curbed the actions of animal rights extremists, and also underlined his support for stem cell research.